Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
AZ Central19d
Best of the Week: Five Marion-area boys basketball teams headed to districts this week
MARION — Coming out of the weekend, five Marion-area boys basketball teams remain alive entering ... The Knights also played ...
BioSpace4d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Yahoo Finance4d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead Sciences's senior vice president and virology therapeutic area head Dr Jared Baeten said: “Gilead is continuing to innovate in our work to develop additional person-centered long-acting ...
Morningstar4d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
“Gilead is fueling the next wave of innovation in HIV to help end the epidemic globally,” said Jared Baeten, MD, PhD, Senior Vice President, Virology Therapeutic Area Head. “Our ...
Morningstar5d
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Virology Therapeutic Area Head, Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence ...
PharmiWeb23d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq ... important treatment option for people living with the rare liver disease in the European Economic Area (EEA). “Today’s decision reinforces the ...
Yahoo Finance24d
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
February 20, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... living with the rare liver disease in the European Economic Area (EEA). "Today’s decision reinforces the clinical benefit ...
Insider Monkey4d
Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
In this article, we are going to take a look at where Gilead Sciences Inc (NASDAQ ... and if you dig in on the fun this might be an area where you want to take a a closer look.” ...
The Marion Star26d
Boys Best of the Week: Elgin earns its fourth KMAC wrestling championship in a row
Elgin only competes in wrestling in the KMAC. Others from the area winning titles were Mount Gilead's Rocco Castricone at 106, Northmor's Ethan Amens at 120, Northmor's Ryan Parsons at 150 ...
Clinical Trials Arena on MSN4d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Nasdaq3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Virology Therapeutic Area Head. “Our contributions to CROI spotlight our dedication to scientific discovery, reflect our commitment to addressing the diverse treatment needs and preferences of ...